Related Experiment Videos
Radioimmunodetection and radioimmunotherapy
Cancer Investigation
|January 1, 1984
Abstract:
The development of monoclonal antibodies that recognize tumor-associated antigens has led to significantly greater practical possibilities for producing highly specific radiolabeled antibodies for diagnosis and therapy of human tumors. A number of problems remain before this technique will be ready for routine clinical application however. Achieving the high target to background ratio that are predicted on theoretical grounds is a major challenge in cancer investigation.
Insights
Monoclonal antibodies offer promising cancer diagnosis and therapy. However, achieving high target-to-background ratios remains a key challenge for clinical application.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Monoclonal antibodies targeting tumor-associated antigens show potential for cancer diagnosis and therapy.
- Radiolabeling these antibodies enhances specificity for human tumor applications.
Purpose of the Study:
- To explore the practical applications of radiolabeled monoclonal antibodies in cancer diagnosis and therapy.
- To identify challenges hindering the routine clinical use of this technology.
Main Methods:
- Development of specific monoclonal antibodies against tumor-associated antigens.
- Radiolabeling techniques for antibody conjugation.
- Evaluation of target-to-background ratios in preclinical or clinical settings.
Main Results:
- Significant practical possibilities exist for producing highly specific radiolabeled antibodies.
- A major challenge is achieving the theoretically predicted high target-to-background ratios.
Conclusions:
- Radiolabeled monoclonal antibodies hold promise for cancer management.
- Further research is needed to overcome current limitations for routine clinical application.